{"schema_version":"secwatch.filing_event.v1","accession":"0000950123-22-010618","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.810695+00:00","generated_at":"2026-06-22T20:38:29.406144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance","bullets":["Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.","EPS $2.15, +6% reported, +13% comparable; operating margin 29.1%, +100 bps comparable.","Record global premium instrument placements, +10% YoY; installed base +14%.","FY2022 guidance: revenue growth 3.5-4.5% reported, 6.5-7.5% organic; EPS $7.74-$7.98.","Foreign currency headwinds: ~4% revenue impact, ~$0.25 EPS impact for FY2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950123-22-010618","json":"https://secwatch.observer/filing/0000950123-22-010618.json","markdown":"https://secwatch.observer/filing/0000950123-22-010618.md","text":"https://secwatch.observer/filing/0000950123-22-010618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/0000950123-22-010618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/idxx-8k_20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:38:29.406144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b0abf5c8fca1b0dc8e78a4798d9736482a4dce1","claim":"IDEXX LABORATORIES INC /DE reported the quarter ended September 30, 2022 results: revenue $842 million, EPS $2.15. Guidance reaffirmed.","evidence_excerpt":"The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group (\"CAG\") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/0000950123-22-010618-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$842 million"},{"label":"EPS","value":"$2.15"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}